Premium
Submaximal endurance exercise performance during enalapril treatment in patients with essential hypertension
Author(s) -
Baak Marlene A,
Mooij Jaap M V,
Wijnen Joseph A G,
Tan Frans S
Publication year - 1991
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1038/clpt.1991.128
Subject(s) - enalapril , heart rate , essential hypertension , blood pressure , medicine , crossover study , angiotensin converting enzyme , endocrinology , cardiology , placebo , alternative medicine , pathology
In a double‐blind randomized crossover study of 10 patients with mild essential hypertension, the influence of antihypertensive treatment with the angiotensin‐I converting enzyme inhibitor enalapril (a single dose of 10 mg • day −1 ) on submaximal endurance exercise performance at a work rate eliciting a heart rate of 150 beats/min was studied. Resting and exercise blood pressure were significantly reduced during enalapril therapy. Heart rate was unaffected. Submaximal endurance exercise performance was reduced by 12% ( p = 0.06). Plasma lactate concentrations were significantly increased and serum nonesterified fatty acid concentrations were decreased during exercise in patients receiving enalapril treatment. Plasma glucose and potassium levels and serum glycerol concentrations were not influenced by enalapril treatment. Because the impairment of endurance performance during enalapril treatment is relatively small compared with the reductions caused by other antihypertensive agents, such as β‐adrenoceptor blocking agents or diuretics, it is of minor clinical importance for most physically active patients with hypertension. Clinical Pharmacology and Therapeutics (1991) 50, 221–227; doi: 10.1038/clpt.1991.128